AR119784A1 - Agentes antipalúdicos - Google Patents
Agentes antipalúdicosInfo
- Publication number
- AR119784A1 AR119784A1 ARP200102325A ARP200102325A AR119784A1 AR 119784 A1 AR119784 A1 AR 119784A1 AR P200102325 A ARP200102325 A AR P200102325A AR P200102325 A ARP200102325 A AR P200102325A AR 119784 A1 AR119784 A1 AR 119784A1
- Authority
- AR
- Argentina
- Prior art keywords
- 6alkyl
- 6alkylcooh
- haloc1
- cooh
- hydrogen
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 23
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 18
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 15
- 229910052739 hydrogen Inorganic materials 0.000 abstract 13
- 239000001257 hydrogen Substances 0.000 abstract 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 13
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 12
- 229910052736 halogen Inorganic materials 0.000 abstract 12
- 150000002367 halogens Chemical group 0.000 abstract 12
- -1 C1−6alkylCOOH Chemical group 0.000 abstract 10
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 abstract 2
- 101710141115 Plasmepsin IX Proteins 0.000 abstract 2
- 101710170193 Plasmepsin X Proteins 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 201000004792 malaria Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 230000000078 anti-malarial effect Effects 0.000 abstract 1
- 239000003430 antimalarial agent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente proporciona métodos para el tratamiento contra la malaria que comprende la administración de compuesto de la fórmula (1) o una sal de este farmacéuticamente aceptable, a un sujeto que lo necesite, en donde las variables son como se definen en la presente. La presente también proporciona usos de los compuestos de la fórmula (1), como se define en la presente, para inhibir la actividad de plasmepsina X, plasmepsina IX o plasmepsina X y IX, para el tratamiento contra la infección de Pasmodium, y para el tratamiento contra la malaria. También se proporcionan métodos de tratamiento que comprenden además la administración de uno o más compuestos antipalúdicos. Reivindicación 1: Un compuesto que tiene la fórmula estructural (1) o una sal de este farmacéuticamente aceptable, en donde: X es un enlace, C(R¹⁴)₂, O, S, SO, SO₂ o NH; Y es CR⁹ o N, en donde cuando Y es N, Z es CR¹¹ y V es CR¹⁰; V es CR¹⁰ o N, en donde cuando V es N, Z es CR¹¹ y Y es CR⁹; Z es CR¹¹ o N, en donde cuando Z es N, V es CR¹⁰ y Y es CR⁹; R¹ es un heterocicloalquilo, C₃₋₁₂cicloalquilo, arilo, C₁₋₆alquilarilo o cuando se toma con R², y el nitrógeno al cual están unidos, forma un anillo que contiene nitrógeno, en donde el heterocicloalquilo, C₃₋₁₂cicloalquilo, arilo, C₁₋₆alquilarilo o anillo que contiene nitrógeno está sustituido o no sustituido con 1 a 5 sustituyentes seleccionados independientemente del grupo que consiste en halógeno, CN, OH, C₁₋₆alcoxi, C₁₋₆alquiloOC₁₋₆alquilo, C₁₋₆alquilCOOH, COOH, oxo, COOC₁₋₆alquilo, C₁₋₆alquilCOOC₁₋₆alquilo, C₃₋₆cicloalquilo, C₁₋₆alquilC₃₋₆cicloalquilo, arilo, C₁₋₆alquilo, C₁₋₆alquilOhaloC₁₋₆alquilo, haloC₁₋₆alquilo, C₁₋₆alquilOH, CON(R⁷)(R⁸), N(R⁷)(R⁸) y C₁₋₆-alquilN(R⁷)(R⁸); R² es hidrógeno, C₁₋₆alquilCOOH, COOH, C₃₋₆cicloalquilo, C₁₋₆alquilo, haloC₁₋₆alquilo o C₁₋₆alquilOH o cuando se toma con R¹, y el nitrógeno al cual están unidos, forma un anillo que contiene nitrógeno, en donde el anillo que contiene nitrógeno está sustituido o no sustituido con 1 a 5 sustituyentes seleccionados independientemente del grupo que consiste en halógeno, CN, OH, C₁₋₆alcoxi, C₁₋₆alquilOC₁₋₆alquilo, C₁₋₆alquilCOOH, COOH, oxo, COOC₁₋₆alquilo, C₃₋₆cicloalquilo, C₁₋₆alquilo, haloC₁₋₆alquilo, C₁₋₆alquilOH, CON(R⁷)(R⁸), N(R⁷)(R⁸) y C₁₋₆alquilN(R⁷)(R⁸); R³ es hidrógeno, halógeno, CN, OH, C₁₋₆alcoxi, C₁₋₆alquilOC₁₋₆alquilo, C₁₋₆alquilCOOH, COOH, C₃₋₆cicloalquilo, C₁₋₆alquilo, haloC₁₋₆alquilo, C₁₋₆alquilOH, CON(R⁷)(R⁸), N(R⁷)(R⁸), C₁₋₆alquilN(R⁷)(R⁸), C₁₋₆alquil(OCH₂CH₂)ₙN(R⁷)(R⁸) o C₁₋₆alquilOhaloC₁₋₆alquil o cuando se toma con R⁴ forma un C₃₋₆cicloalquilo o C₃₋₆heterocicloalquilo; R⁴ es hidrógeno, halógeno, CN, OH, C₁₋₆alcoxi, C₁₋₆alquilOC₁₋₆alquilo, C₁₋₆alquilCOOH, COOH, C₃₋₆cicloalquilo, C₁₋₆alquilo, haloC₁₋₆alquilo, C₁₋₆alquilOH, CON(R⁷)(R⁸), N(R⁷)(R⁸), C₁₋₆alquilN(R⁷)(R⁸), C₁₋₆alquil(OCH₂CH₂)ₙN(R⁷)(R⁸) o C₁₋₆alquilOhaloC₁₋₆alquil o cuando se toma con R³ forma un C₃₋₆cicloalquilo o C₃₋₆heterocicloalquilo; R⁵ es hidrógeno, halógeno, CN, OH, C₁₋₆alcoxi, C₁₋₆alquilOC₁₋₆alquilo, C₁₋₆alquilCOOH, COOH, C₃₋₆cicloalquilo, C₁₋₆alquilo, haloC₁₋₆alquilo, C₁₋₆alquiloOH, CON(R⁷)(R⁸), N(R⁷)(R⁸) o C₁₋₆alquilN(R⁷)(R⁸) o cuando se toma con R⁶ forma un C₃₋₆cicloalquilo o C₃₋₆heterocicloalquilo; R⁶ es hidrógeno, halógeno, CN, OH, C₁₋₆alcoxi, C₁₋₆alquilOC₁₋₆alquilo, C₁₋₆alquilCOOH, COOH, C₃₋₆cicloalquilo, C₁₋₆alquilo, haloC₁₋₆alquilo, C₁₋₆alquilOH, CON(R⁷)(R⁸), N(R⁷)(R⁸) o C₁₋₆alquilN(R⁷)(R⁸) o cuando se toma con R⁵ forma un C₃₋₆cicloalquilo o C₃₋₆heterocicloalquilo; R⁷ es hidrógeno, C₁₋₆alquilCOOH, COOH, C₃₋₆cicloalquilo, C₁₋₆alquilo, haloC₁₋₆alquilo, C₁₋₆alquilOH, COC₁₋₆alquilo o COOC₁₋₆alquilo; R⁸ es hidrógeno, C₁₋₆alquilCOOH, COOH, C₃₋₆cicloalquilo, C₁₋₆alquilo, haloC₁₋₆alquilo, C₁₋₆alquilOH, COC₁₋₆alquilo o COOC₁₋₆alquilo; R⁹ es hidrógeno, halógeno, CN, OH, C₁₋₆alcoxi, C₁₋₆alquilOC₁₋₆alquilo, C₁₋₆alquilCOOH, COOH, C₃₋₆cicloalquilo, C₁₋₆alquilo, haloC₁₋₆alquilo, C₁₋₆alquilOH, CON(R⁷)(R⁸), N(R⁷)(R⁸) o C₁₋₆alquilN(R⁷)(R⁸); R¹⁰ es hidrógeno, halógeno, CN, OH, C₁₋₆alcoxi, C₁₋₆alquilOC₁₋₆alquilo, C₁₋₆alquilCOOH, COOH, C₃₋₆cicloalquilo, C₁₋₆alquilo, haloC₁₋₆alquilo, C₁₋₆alquilOH, CON(R⁷)(R⁸), N(R⁷)(R⁸) o C₁₋₆alquilN(R⁷)(R⁸); R¹¹ es hidrógeno, halógeno, CN, OH, C₁₋₆alcoxi, C₁₋₆alquilOC₁₋₆alquilo, C₁₋₆alquilCOOH, COOH, C₃₋₆cicloalqquilo, C₁₋₆alquilo, haloC₁₋₆alquilo, C₁₋₆alquilOH, CON(R⁷)(R⁸), N(R⁷)(R⁸) o C₁₋₆alquilN(R⁷)(R⁸); R¹² es hidrógeno, halógeno, CN, OH, C₁₋₆alcoxi, C₁₋₆alquilOC₁₋₆alquilo, C₁₋₆alquilCOOH, COOH, C₃₋₆cicloalquilo, C₁₋₆alquilo, haloC₁₋₆alquilo, C₁₋₆alquilOH, CON(R⁷)(R⁸), N(R⁷)(R⁸) o C₁₋₆alquilN(R⁷)(R⁸); R¹³ es hidrógeno, halógeno, CN, OH, C₁₋₆alcoxi, C₁₋₆alquilOC₁₋₆alquilo, C₁₋₆alquilCOOH, COOH, C₃₋₆cicloalquilo, C₁₋₆alquilo, haloC₁₋₆alquilo, C₁₋₆alquilOH, CON(R⁷)(R⁸), N(R⁷)(R⁸) o C₁₋₆alquilN(R⁷)(R⁸); cada caso de R¹⁴ se selecciona independientemente del grupo que consiste en hidrógeno, halógeno, CN, OH, C₁₋₆alcoxi, C₁₋₆alquilOC₁₋₆alquilo, C₁₋₆alquilCOOH, COOH, C₃₋₆cicloalquilo, C₁₋₆alquilo, haloC₁₋₆alquilo, C₁₋₆alquilOH, CON(R⁷)(R⁸), N(R⁷)(R⁸) y C₁₋₆alquil(R⁷)(R⁸); n es 1, 2, 3 ó 4; y m es 0, 1 ó 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2019/100781 WO2021026884A1 (en) | 2019-08-15 | 2019-08-15 | Antimalarial agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119784A1 true AR119784A1 (es) | 2022-01-12 |
Family
ID=74570489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102325A AR119784A1 (es) | 2019-08-15 | 2020-08-14 | Agentes antipalúdicos |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US12350270B2 (es) |
| EP (1) | EP4013742A4 (es) |
| JP (1) | JP7116859B2 (es) |
| KR (1) | KR102752456B1 (es) |
| CN (1) | CN114555564B (es) |
| AR (1) | AR119784A1 (es) |
| AU (1) | AU2020328678B2 (es) |
| BR (1) | BR112022002692A2 (es) |
| CA (1) | CA3147665C (es) |
| CL (1) | CL2022000329A1 (es) |
| CO (1) | CO2022001342A2 (es) |
| CR (1) | CR20220067A (es) |
| DO (1) | DOP2022000037A (es) |
| EC (1) | ECSP22011746A (es) |
| GE (2) | GEAP202415903A (es) |
| IL (1) | IL290525B2 (es) |
| JO (1) | JOP20220038A1 (es) |
| MX (1) | MX2022001768A (es) |
| PH (1) | PH12022550350A1 (es) |
| TW (1) | TWI881998B (es) |
| UA (1) | UA128074C2 (es) |
| WO (2) | WO2021026884A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023102747A1 (en) * | 2021-12-07 | 2023-06-15 | Merck Sharp & Dohme Llc | Antimalarial agents |
| WO2022066545A1 (en) * | 2020-09-23 | 2022-03-31 | Merck Sharp & Dohme Corp. | Methods of chemovaccination against plasmodium infections |
| WO2022169790A1 (en) * | 2021-02-05 | 2022-08-11 | Merck Sharp & Dohme Llc | Chemovaccination against plasmodium infection with selective plasmepsin x inhibitors |
| WO2024254795A1 (en) * | 2023-06-14 | 2024-12-19 | Merck Sharp & Dohme Llc | Antimalaria agents |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005058311A1 (en) | 2003-12-15 | 2005-06-30 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7763609B2 (en) * | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| JP2009513670A (ja) | 2005-10-31 | 2009-04-02 | シェーリング コーポレイション | アスパルチルプロテアーゼインヒビター |
| UA108363C2 (uk) * | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| EA034196B1 (ru) * | 2015-11-25 | 2020-01-16 | Юсб Байофарма Спрл | Производные иминотетрагидропиримидинона в качестве ингибиторов плазмепсина v |
| US11766435B2 (en) * | 2016-02-18 | 2023-09-26 | Merck Sharp & Dohme Llc | N3-substituted iminopyrimidinones as antimalarial agents |
| US20190046507A1 (en) | 2016-02-18 | 2019-02-14 | Merck Sharp & Dohme Corp. | Compounds for the treatment of malaria |
| GB201603104D0 (en) * | 2016-02-23 | 2016-04-06 | Ucb Biopharma Sprl | Therapeutic agents |
| GB201906804D0 (en) * | 2019-05-14 | 2019-06-26 | Ucb Biopharma Sprl | Therapeutic agents |
| WO2021155612A1 (en) * | 2020-02-09 | 2021-08-12 | Merck Sharp & Dohme Corp. | Antimalarial agents |
-
2019
- 2019-08-15 WO PCT/CN2019/100781 patent/WO2021026884A1/en not_active Ceased
-
2020
- 2020-07-21 IL IL290525A patent/IL290525B2/en unknown
- 2020-07-21 PH PH1/2022/550350A patent/PH12022550350A1/en unknown
- 2020-07-21 BR BR112022002692A patent/BR112022002692A2/pt unknown
- 2020-07-21 GE GEAP202415903A patent/GEAP202415903A/en unknown
- 2020-07-21 CN CN202080072179.5A patent/CN114555564B/zh active Active
- 2020-07-21 JO JOP/2022/0038A patent/JOP20220038A1/ar unknown
- 2020-07-21 UA UAA202200963A patent/UA128074C2/uk unknown
- 2020-07-21 MX MX2022001768A patent/MX2022001768A/es unknown
- 2020-07-21 GE GEAP202015903A patent/GEP20257744B/en unknown
- 2020-07-21 AU AU2020328678A patent/AU2020328678B2/en active Active
- 2020-07-21 JP JP2022508854A patent/JP7116859B2/ja active Active
- 2020-07-21 CA CA3147665A patent/CA3147665C/en active Active
- 2020-07-21 CR CR20220067A patent/CR20220067A/es unknown
- 2020-07-21 EP EP20852190.6A patent/EP4013742A4/en active Pending
- 2020-07-21 WO PCT/CN2020/103178 patent/WO2021027502A1/en not_active Ceased
- 2020-07-21 KR KR1020227007941A patent/KR102752456B1/ko active Active
- 2020-07-21 US US17/633,655 patent/US12350270B2/en active Active
- 2020-08-14 AR ARP200102325A patent/AR119784A1/es unknown
- 2020-08-14 TW TW109127798A patent/TWI881998B/zh active
-
2022
- 2022-02-08 CL CL2022000329A patent/CL2022000329A1/es unknown
- 2022-02-10 CO CONC2022/0001342A patent/CO2022001342A2/es unknown
- 2022-02-11 DO DO2022000037A patent/DOP2022000037A/es unknown
- 2022-02-14 EC ECSENADI202211746A patent/ECSP22011746A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119784A1 (es) | Agentes antipalúdicos | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR088352A1 (es) | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina | |
| AR112834A1 (es) | Derivados de rapamicina | |
| AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
| AR042956A1 (es) | Inhibidores de girasa y usos de los mismos | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| AR127404A1 (es) | Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| PE20240775A1 (es) | Compuestos antivirales | |
| CO4900063A1 (es) | Piridinas substituidas como inhibidores selectivos de ciclo- oxi-genasa2 | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| AR089774A1 (es) | Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR049399A1 (es) | Difenilimidazopirimidina e -imidazol aminas como inhibidores de b-secretasa y metodo de obtencion de los mismos | |
| AR107293A1 (es) | COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g | |
| AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
| AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR099914A1 (es) | Derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR104555A1 (es) | SULFONAS TRICÍCLICAS COMO MODULARES DE RORg | |
| ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
| AR095351A1 (es) | Inhibidores de histona desacetilasa (hdac) | |
| MX2018014944A (es) | Tratamiento para la enfermedad de parkinson. | |
| CO6300944A2 (es) | Derivado de hidroxi-quinoxalin-carboxamida | |
| AR068381A1 (es) | Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6 |